ARCHIVES

CMS Looks At Coverage of Two Agents Approved on Surrogate Endpoints

This article is from The Cancer Letter archive.

Vol. 29 No. 08 | February 21, 2003

Download PDF Visit The Full Archive

Related Articles

Navelbine+Herceptin: 78% Response In Breast Cancer

November 29, 2002

NCI Cooperative Group Clinical Trials Approved

December 25, 2009

NIH Seeks Candidates For Research Grants Division Director

September 8, 1995

Coordination, Funding Lacking In National Cancer Program: Report

October 7, 1994

Asks BSC For Advice On Centers Funding, Other Pressing Issues, But Doesn’t Get Any

March 30, 1990

Legacy CEO Cheryl Healton says foundation could serve as funder for research on “potentially reduced-exposure products.”

October 29, 2004